Sellas Life Sciences Stock Jumps 15% on REGAL Catalyst
June 30, 2026·about 3 hours ago·via Stocktwits
Sellas Life Sciences is drawing significant retail investor attention as traders eye the REGAL Phase 3 trial results as a potential market catalyst. The SLS stock surged 15% as retail traders build positions ahead of the upcoming clinical trial data. The biotech company's stock momentum reflects investor optimism around the Phase 3 program's potential impact on the company's future prospects and valuation. Read more about this...